Core Viewpoint - VerticalScope Holdings Inc. reported its financial results for the fourth quarter ended December 31, 2025, emphasizing the resilience of its business model and the strength of its community-driven audience [1]. Financial Performance - The company announced its financial results for Q4, indicating a strong performance during the quarter [1]. - The results reflect the underlying resilience of the business model, showcasing the effectiveness of its cloud-based digital platform for online enthusiast communities [1].

Core Viewpoint - VerticalScope Holdings Inc. is set to release its fourth quarter and full year 2025 financial results on March 3, 2026, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call and webcast scheduled for 8:00 a.m. ET on March 4, 2026 [1] - Registration for the live call and webcast is available through a provided link [1]

Industry Overview - The Zacks Computer - Services industry includes companies providing cloud and software-based solutions, including consulting, research, security, and business support solutions [2] - Participants serve various sectors such as intelligence, defense, government agencies, banking, financial services, insurance, healthcare, and media [2] Current Trends - The shift towards remote and hybrid work is driving demand for cloud and cost-efficient business support solutions, enhancing industry growth prospects [3] - Increasing cyberattacks are creating a heightened need for cybersecurity solutions, particularly within government agencies [4] - Regulatory compliance is becoming more complex, leading to increased demand for services that help businesses adhere to governmental and industry norms [5] Industry Performance - The Zacks Computer - Services industry ranks 47, placing it in the top 19% of over 244 Zacks industries, indicating positive near-term prospects [6][7] - The industry's earnings outlook is optimistic, with a 7.7% increase in the Zacks Consensus Estimate for 2026 earnings since March 31, 2025 [8] Stock Market Performance - Over the past year, the industry has underperformed compared to the broader Zacks Computer and Technology sector and the S&P 500, with a rise of 10.7% versus 19.7% and 27.6% respectively [11] - The industry is currently trading at a forward 12-month P/E of 16.85X, lower than the S&P 500's 23.51X and the sector's 27.94X [14] Notable Companies - **PDF Solutions (PDFS)**: Focuses on data solutions for semiconductor and electronics ecosystems, benefiting from increasing complexity in manufacturing processes and investments in AI-driven collaboration [16][17] - **WidePoint (WYY)**: Provides Technology Management as a Service (TMaaS) and is positioned to benefit from a growing addressable market worth $36 billion, driven by remote work and cybersecurity needs [22][23] - **Forian (FORA)**: Offers data science-driven solutions to healthcare and financial services, with expected revenues between $28 million and $30 million for 2025, indicating a growth of 39-40% from 2024 [26][27]

Forian Inc. Special Meeting Summary Company Overview - **Company Name**: Forian Inc. - **Stock Symbol**: NasdaqCM:FORA - **Meeting Date**: January 08, 2026 - **Meeting Type**: Extraordinary General Meeting Key Points Meeting Proceedings - The meeting was called to order by Max Wygod, CEO and Chairman, at 12:00 PM ET, with several board members and executives present [2][4] - Stockholders were informed that questions could be submitted online, but only relevant questions would be addressed [3] Voting and Proposals - A quorum was established with 31,072,252 shares of common stock issued and outstanding, allowing the meeting to proceed [5] - The first proposal was to re-domicile the company from Delaware to Maryland, requiring a majority vote for approval [6] - The polls for voting on Proposal One were opened and closed at 12:06 PM ET, with the proposal receiving the affirmative vote of a majority of the voting power of the outstanding shares [8] Results and Conclusion - Proposal One was approved, negating the need for Proposal Two regarding adjournment to solicit additional proxies [8] - The final certified results of the vote will be reported in a Form 8-K to be filed with the SEC and posted on the company’s website [8] Additional Information - The meeting included a certified list of stockholders provided by Broadridge, ensuring transparency in the voting process [5] - The agenda and rules of conduct were made available on the virtual stockholder meeting website for convenience [4]

Core Insights - Forian Inc. is facing significant financial challenges with a negative Return on Invested Capital (ROIC) of -13.42% and a ROIC to Weighted Average Cost of Capital (WACC) ratio of -1.52, indicating it is not generating returns above its cost of capital [1][6] Company Performance - Forian Inc. has a ROIC of -13.42% and a WACC of 8.81% [1] - The ROIC to WACC ratio for Forian is -1.52, showing underperformance in generating returns [1][6] Peer Comparison - Ikena Oncology, Inc. has a ROIC of -36.02% and a WACC of 6.18%, resulting in a ROIC to WACC ratio of -5.83 [2] - Finch Therapeutics Group, Inc. reports a ROIC of -38.62% against a WACC of 6.18%, leading to a ratio of -6.25 [2] - NeuroPace, Inc. has a ROIC of -20.32% and a WACC of 12.43%, resulting in a ROIC to WACC ratio of -1.63, indicating it is relatively closer to breaking even [3] - Eledon Pharmaceuticals, Inc. has a ROIC of -75.00% and a WACC of 7.50%, leading to a ROIC to WACC ratio of -10.00 [4] - Werewolf Therapeutics, Inc. reports a ROIC of -87.96% against a WACC of 9.55%, resulting in a ratio of -9.21 [4] Industry Overview - The industry is facing widespread challenges, with all mentioned companies struggling to generate returns that exceed their cost of capital [5][6] - NeuroPace, Inc. shows the most potential for improvement among its peers, with the least negative ROIC to WACC ratio of -1.63 [5][6]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Viewpoint - Forian Inc. is set to discuss its third quarter 2025 financial results, including a revenue outlook for the full year 2025, during a conference call with key executives participating [1]. Financial Performance - The management will provide an estimate of its full year 2025 revenue outlook, emphasizing the challenges in accurately predicting future financial performance due to various assumptions and internal estimates [2]. - There is a significant risk that actual results could differ materially from the outlook provided, highlighting the uncertainty in financial forecasting [2]. Forward-Looking Statements - Any forward-looking statements made during the call represent the company's views as of the date of the call, with no obligation to update them except as required by law [3]. - The company will use terms such as estimates, projected, expect, and anticipate to identify forward-looking statements related to future growth and performance [3].

Financial Data and Key Metrics Changes - Forian reported Q3 2025 revenue of $7.76 million, a 66% increase year over year, driven by the Kyber Data Science acquisition and growth in health economics and outcomes research projects [6][10] - The net loss for the quarter was $151,000, compared to a net loss of $205,000 in the prior year, indicating improved operating leverage [8][11] - Adjusted EBITDA for Q3 2025 was $471,000, up from $186,000 in the same quarter last year, reflecting higher revenues and improved operational performance [8][12] - The company ended the period with $28.2 million in cash and marketable securities and $29.2 million in working capital [12] Business Line Data and Key Metrics Changes - The acquisition of Kyber contributed approximately $2 million, or 43%, to the revenue growth, with the remainder coming from organic growth in the life sciences data business [11] - Forian's Data Factory continues to be a critical differentiator, integrating data from various sources to provide a unified view of the healthcare ecosystem [7] Market Data and Key Metrics Changes - Life science companies are increasingly using Forian's data to understand real-world therapy performance and support evidence generation for regulators and payers [6] - Health service organizations and financial clients are leveraging Forian's data to monitor utilization trends and forecast demand [7] Company Strategy and Development Direction - Forian aims to strengthen its position in healthcare analytics and real-world evidence generation, focusing on creating scalable products that deliver differentiated insights [9] - The company plans to continue investing in long-term data relationships and new offerings to enhance its analytical capabilities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year 2025 revenue near the high end of the previously communicated range of $28 million to $30 million, reflecting a growth of 39%-49% over the previous year [8][14] - The company remains focused on driving sustainable growth and enhancing profitability in the evolving market for real-world data and analytics [9] Other Important Information - The company does not intend to discuss updates related to the previously announced take-private offer during this call [5] Q&A Session Summary - No questions were asked during the Q&A session, and the call concluded without further inquiries [15]

Q3 2025 Financial Results Revenue and Adjusted EBITDA | | | | ($000's) Three Months Ended September 30, | | | | | ($000's) Nine Months Ended September 30, | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | Period-over- | | | | | Period-over | | | 2025 | | 2024 | | Period % | | 2025 | 2024 | | Period % | | | Unaudited | | Unaudited | | Change | | Unaudited | Unaudited | | Change | | Revenue | $ | 7,762 | $ | 4,686 | 66% | $ | 22,294 | $ | 14,341 | 55% | | Net loss | $ | (15 ...